Wegovy

Wegovy does not produce chemical withdrawal. There is no shaking, no rebound anxiety from receptor adaptation, no seizure risk.

Wegovy is semaglutide 2.4 mg dosed once weekly for chronic weight management. The phase 3 STEP 1 trial (Wilding et al.

Wegovy and Zepbound are the two FDA-approved brand-name obesity medications dominating the market in 2026.

Sleep problems on Wegovy are real but mild for most people. The STEP 1 trial (Wilding et al.

The Wegovy shortage that began in 2022 was officially declared resolved by the FDA in February 2025.

The first week on Wegovy is mostly an adjustment period, not a weight loss week.

Six months on Wegovy is where the bulk of the heavy lifting happens.

Three months on Wegovy lands most patients at 7 to 10 percent body weight loss and 2 to 3 dose escalations into the protocol.

Month 2 on Wegovy is when most patients stop wondering whether the medication is working.